Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDN and tDCS in Fibromyalgia
NCT04502251Phase 3Completed
- Sponsor
- Centro Superior de Estudios Universitarios La Salle
- Start
- Aug 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of naltrexone in fibromyalgia (FM) (4 arms), sponsored by Centro Superior de Estudios Universitarios La Salle. Primary endpoint: Pain in Visual Analog Scale at 26 days. Started Aug 2018; status: completed.
02
Drugs
naltrexone
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT04502251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04502251.